MA40737A - Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 - Google Patents
Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1Info
- Publication number
- MA40737A MA40737A MA040737A MA40737A MA40737A MA 40737 A MA40737 A MA 40737A MA 040737 A MA040737 A MA 040737A MA 40737 A MA40737 A MA 40737A MA 40737 A MA40737 A MA 40737A
- Authority
- MA
- Morocco
- Prior art keywords
- determinants
- immunotherapy
- blocked
- cancer response
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462083088P | 2014-11-21 | 2014-11-21 | |
US201562132381P | 2015-03-12 | 2015-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40737A true MA40737A (fr) | 2017-07-04 |
Family
ID=56014697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040737A MA40737A (fr) | 2014-11-21 | 2015-11-22 | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
Country Status (9)
Country | Link |
---|---|
US (3) | US20180291074A1 (fr) |
EP (2) | EP3220950A4 (fr) |
JP (3) | JP7173733B2 (fr) |
CN (2) | CN107206064B (fr) |
AU (2) | AU2015349644B2 (fr) |
CA (1) | CA2968059A1 (fr) |
HK (1) | HK1244440A1 (fr) |
MA (1) | MA40737A (fr) |
WO (1) | WO2016081947A2 (fr) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4169951A1 (fr) | 2008-12-09 | 2023-04-26 | F. Hoffmann-La Roche AG | Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t |
DK3081576T3 (da) | 2013-12-12 | 2019-10-21 | Shanghai hengrui pharmaceutical co ltd | Pd-1-antistof, antigenbindende fragment deraf og medicinsk anvendelse deraf |
DK3212670T3 (da) | 2014-10-29 | 2021-03-22 | Five Prime Therapeutics Inc | Kombinationsterapi mod cancer |
MA40737A (fr) * | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
IL259931B2 (en) | 2015-12-16 | 2024-02-01 | Gritstone Bio Inc | Identification of neo-antigens, preparation, and use |
JP2019509282A (ja) | 2016-02-29 | 2019-04-04 | ファウンデーション・メディシン・インコーポレイテッド | 癌の治療方法 |
KR102500659B1 (ko) | 2016-02-29 | 2023-02-16 | 제넨테크, 인크. | 암에 대한 치료 및 진단 방법 |
KR102413032B1 (ko) * | 2016-03-01 | 2022-06-24 | 노쓰 캐롤라이나 스테이트 유니버시티 | 마이크로니들 패치-보조된 전달에 의한 향상된 암 면역요법 |
WO2017150595A1 (fr) * | 2016-03-02 | 2017-09-08 | 東レ株式会社 | Inducteur d'immunité |
BR112018074463A2 (pt) | 2016-05-27 | 2019-03-06 | Agenus Inc. | anticorpos anti-tim-3 e métodos de uso dos mesmos. |
JP6910653B2 (ja) * | 2016-07-01 | 2021-07-28 | 国立大学法人東北大学 | 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法 |
JP6995842B2 (ja) * | 2016-08-25 | 2022-01-17 | ナントミクス,エルエルシー | 免疫療法マーカー及びその使用 |
CN110418851A (zh) | 2016-10-06 | 2019-11-05 | 基因泰克公司 | 癌症的治疗和诊断方法 |
WO2018067937A1 (fr) * | 2016-10-07 | 2018-04-12 | Omniseq, Inc. | Procédés et systèmes pour déterminer des thérapies personnalisées |
US20190369096A1 (en) * | 2017-01-13 | 2019-12-05 | Nantbio, Inc. | Validation of neoepitope-based treatment |
CA3050109A1 (fr) * | 2017-01-18 | 2018-07-26 | Ichan School Of Medicine At Mount Sinai | Neoantigenes et leurs utilisations dans le traitement du cancer |
BR112019015797A2 (pt) | 2017-02-01 | 2020-03-17 | Modernatx, Inc. | Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação |
JP7162600B2 (ja) * | 2017-02-06 | 2022-10-28 | ノヴァルティス アーゲー | 免疫療法に対する応答を予測する方法 |
EP3494235A1 (fr) * | 2017-02-17 | 2019-06-12 | Stichting VUmc | Diagnostic et sélection de thérapie améliorés par l'intelligence en essaim pour le cancer à l'aide de plaquettes éduquées contre les tumeurs |
AU2018240199A1 (en) * | 2017-03-20 | 2019-10-17 | Genocea Biosciences, Inc. | Treatment methods |
SG11201908396PA (en) * | 2017-03-31 | 2019-10-30 | Bristol Myers Squibb Co | Methods of treating tumor |
GB201710815D0 (en) * | 2017-07-05 | 2017-08-16 | Francis Crick Inst Ltd | Method |
CN111492245A (zh) | 2017-07-21 | 2020-08-04 | 基因泰克公司 | 癌症的治疗和诊断方法 |
KR20200033930A (ko) * | 2017-07-28 | 2020-03-30 | 브리스톨-마이어스 스큅 컴퍼니 | 체크포인트 억제제에 대한 예측성 말초 혈액 바이오마커 |
US11421034B2 (en) * | 2017-09-13 | 2022-08-23 | Five Prime Therapeutics, Inc. | Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer |
US20200268831A1 (en) * | 2017-09-15 | 2020-08-27 | The Texas A&M University System | Methods for enhancing immunotherapy in the treatment of cancer |
BR112020005602A2 (pt) | 2017-09-25 | 2020-10-13 | Memorial Sloan Kettering Cancer Center | carga de mutação de tumor |
CA3076918A1 (fr) * | 2017-10-02 | 2019-04-11 | Curematch, Inc. | Procede de prediction de l'antigenicite et/ou de l'immunogenicite d'un neo-peptide derive d'une tumeur, a l'aide de motifs de signature mutationnelle |
CN111465989B (zh) | 2017-10-10 | 2024-06-25 | 磨石生物公司 | 使用热点进行的新抗原鉴别 |
WO2019075251A2 (fr) * | 2017-10-12 | 2019-04-18 | Nantomics, Llc | Score de cancer pour l'évaluation et la prévision de réponse à partir de fluides biologiques |
US20200239577A1 (en) | 2017-10-15 | 2020-07-30 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2019090156A1 (fr) | 2017-11-03 | 2019-05-09 | Guardant Health, Inc. | Normalisation de la charge de mutation tumorale |
JP7245255B2 (ja) * | 2017-11-17 | 2023-03-23 | ジーエムディーエックス カンパニー プロプライエタリー リミテッド | がん治療の有効性を予測するためのシステムおよび方法 |
CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
WO2019109086A1 (fr) * | 2017-12-01 | 2019-06-06 | Illumina, Inc. | Procédés et systèmes de détermination de clonalité par mutation somatique |
US20210054465A1 (en) * | 2018-05-03 | 2021-02-25 | Roche Sequencing Solutions, Inc. | Surrogate marker and method for tumor mutation burden measurement |
JP2021522298A (ja) * | 2018-05-04 | 2021-08-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 癌治療のためのPD−1/PD−L1、TGFβおよびDNA−PKの同時阻害 |
SG11202100344WA (en) | 2018-07-23 | 2021-02-25 | Guardant Health Inc | Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage |
WO2020021119A1 (fr) | 2018-07-27 | 2020-01-30 | F. Hoffmann-La Roche Ag | Procédé de surveillance de l'efficacité d'immunothérapie de patients atteints d'un cancer |
US11673927B2 (en) | 2018-08-29 | 2023-06-13 | Tokyo Metropolitan Institute Of Medical Science | Antitumor agent targeting HGF-regulated tyrosine kinase substrate (HGS) |
CN112930569A (zh) | 2018-08-31 | 2021-06-08 | 夸登特健康公司 | 无细胞dna中的微卫星不稳定性检测 |
AU2019379167A1 (en) * | 2018-11-15 | 2021-06-03 | Personal Genome Diagnostics Inc. | Method of improving prediction of response for cancer patients treated with immunotherapy |
EP3893932A4 (fr) * | 2018-12-12 | 2022-09-07 | Medimmune, LLC | Charge de mutation de tumeur basée sur le sang permettant de prédire la survie globale dans le cancer du poumon non à petites cellules |
EP3982954A4 (fr) * | 2019-06-14 | 2024-01-03 | The Trustees of Columbia University in the City of New York | Inhibiteurs de nt5c2 pour le traitement de la leucémie lymphoblastique aiguë résistante à la chimiothérapie |
GB202003669D0 (en) * | 2020-03-13 | 2020-04-29 | Univ Oxford Innovation Ltd | Method for identifying neo-antigens |
CN115885050A (zh) | 2020-04-28 | 2023-03-31 | 基因泰克公司 | 用于非小细胞肺癌免疫疗法的方法和组合物 |
CN112309502A (zh) * | 2020-10-14 | 2021-02-02 | 深圳市新合生物医疗科技有限公司 | 一种计算肿瘤新抗原负荷的方法及系统 |
WO2022099004A1 (fr) * | 2020-11-06 | 2022-05-12 | The General Hospital Corporation | Procédés pour caractériser des échantillons biologiques |
WO2022235482A1 (fr) * | 2021-05-03 | 2022-11-10 | Rutgers, The State University Of New Jersey | Immunothérapie pour une maladie intestinale inflammatoire et/ou un cancer |
CN113030475B (zh) * | 2021-05-25 | 2021-08-10 | 泛肽生物科技(浙江)有限公司 | 一种基于细胞线粒体质量评估的t细胞pd-1检测方法 |
CN113355424B (zh) * | 2021-07-14 | 2022-03-25 | 江苏先声医学诊断有限公司 | Pcdh11x突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040033497A1 (en) | 2002-08-13 | 2004-02-19 | Alarcon-Riquelme Marta E. | Polymorphisms of PD-1 |
TWI477602B (zh) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
CN102713606A (zh) * | 2009-11-13 | 2012-10-03 | 无限制药股份有限公司 | 用于鉴定、评估、预防和治疗癌症的组合物、试剂盒和方法 |
GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
CN103154034B (zh) * | 2010-04-13 | 2016-06-08 | 塞尔德克斯医疗公司 | 结合人cd27的抗体及其用途 |
US9115402B2 (en) * | 2010-05-14 | 2015-08-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of identifying tumor specific neoantigens |
KR20200075023A (ko) | 2012-05-04 | 2020-06-25 | 화이자 인코포레이티드 | 전립선 관련된 항원 및 백신 기재 면역치료 요법 |
EP2901341B1 (fr) | 2012-09-28 | 2019-04-10 | The University of Connecticut | Identification d'épitopes protecteurs de tumeur pour le traitement de cancers |
AU2014374020A1 (en) * | 2014-01-02 | 2016-08-18 | Memorial Sloan Kettering Cancer Center | Determinants of cancer response to immunotherapy |
KR20190135563A (ko) * | 2014-11-13 | 2019-12-06 | 더 존스 홉킨스 유니버시티 | 관문 차단 및 미소부수체 불안정성 |
MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
BR112020005602A2 (pt) * | 2017-09-25 | 2020-10-13 | Memorial Sloan Kettering Cancer Center | carga de mutação de tumor |
-
2015
- 2015-11-22 MA MA040737A patent/MA40737A/fr unknown
- 2015-11-23 EP EP15861224.2A patent/EP3220950A4/fr not_active Ceased
- 2015-11-23 CN CN201580073049.2A patent/CN107206064B/zh active Active
- 2015-11-23 JP JP2017527368A patent/JP7173733B2/ja active Active
- 2015-11-23 WO PCT/US2015/062208 patent/WO2016081947A2/fr active Application Filing
- 2015-11-23 US US15/528,385 patent/US20180291074A1/en not_active Abandoned
- 2015-11-23 CN CN202210026426.9A patent/CN114672559A/zh active Pending
- 2015-11-23 CA CA2968059A patent/CA2968059A1/fr active Pending
- 2015-11-23 EP EP24157218.9A patent/EP4393546A2/fr active Pending
- 2015-11-23 AU AU2015349644A patent/AU2015349644B2/en active Active
-
2018
- 2018-03-21 HK HK18103939.8A patent/HK1244440A1/zh unknown
-
2019
- 2019-02-22 US US16/283,555 patent/US10993998B2/en active Active
-
2020
- 2020-08-11 JP JP2020135853A patent/JP2020196732A/ja not_active Withdrawn
-
2021
- 2021-03-15 US US17/202,173 patent/US20210308241A1/en active Pending
- 2021-08-09 AU AU2021215099A patent/AU2021215099A1/en active Pending
-
2022
- 2022-08-16 JP JP2022129458A patent/JP2023055625A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2018502828A (ja) | 2018-02-01 |
EP3220950A4 (fr) | 2018-08-29 |
US20180291074A1 (en) | 2018-10-11 |
AU2015349644A1 (en) | 2017-06-15 |
WO2016081947A3 (fr) | 2016-07-07 |
US10993998B2 (en) | 2021-05-04 |
CN114672559A (zh) | 2022-06-28 |
EP3220950A2 (fr) | 2017-09-27 |
US20200040049A1 (en) | 2020-02-06 |
CN107206064B (zh) | 2021-12-21 |
EP4393546A2 (fr) | 2024-07-03 |
WO2016081947A4 (fr) | 2016-09-09 |
JP2020196732A (ja) | 2020-12-10 |
HK1244440A1 (zh) | 2018-08-10 |
CA2968059A1 (fr) | 2016-05-26 |
JP7173733B2 (ja) | 2022-11-16 |
JP2023055625A (ja) | 2023-04-18 |
AU2015349644B2 (en) | 2021-08-19 |
AU2021215099A1 (en) | 2021-08-26 |
WO2016081947A2 (fr) | 2016-05-26 |
CN107206064A (zh) | 2017-09-26 |
US20210308241A1 (en) | 2021-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40737A (fr) | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 | |
SG11201605432RA (en) | Determinants of cancer response to immunotherapy | |
MA43258A (fr) | Liants pd1/ctla4 | |
DK3204417T3 (da) | Cd73-blokering | |
DK3186244T3 (da) | Dioxolananaloger af uridin til behandling af cancer | |
DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
DK3175012T3 (da) | Forbedret aktivering af selvpassiverende metaller | |
DE112015003457A5 (de) | Al-Gusslegierung | |
HK1250719A1 (zh) | 脫氧糖胺的合成 | |
DK3201559T3 (da) | Patronhylster | |
HK1258143A1 (zh) | 和厚朴酚的改進的合成 | |
DK3397352T3 (da) | Antiperspirantsammensætninger | |
DK3273821T3 (da) | Tilpasseligt smykke | |
DK3253407T3 (da) | Brug af hla-b27-homodimere til kræftbehandling | |
KR20180084983A (ko) | 암의 치료를 위한 피리미도-피리미다지논의 용도 | |
FR3040595B3 (fr) | Parasol suspendu demontable | |
ES1137506Y (es) | Helice reductora de perdidas | |
FR3023260B1 (fr) | Ensemble propulsif d'aeronef | |
EP3516081A4 (fr) | Déterminants de la réponse d'un cancer à l'immunothérapie | |
DK3230300T3 (da) | Inhibitorer til inhibering af tumor metastase | |
MA41255A (fr) | Composition de composé salicylate | |
MC200163B1 (fr) | Revêtement pour la protection des supports métalliques | |
IT201700081473A1 (it) | Prevenzione mareggiate | |
FI11432U1 (fi) | Kantosuoja | |
IT201700010606A1 (it) | GenialCombi di Moscarelli |